Prevention of pneumococcal disease through vaccination (Q50992672)

26 March 2018

title

Prevention of pneumococcal disease through vaccination (English)

1 reference

26 March 2018

author name string

Angela Gentile

series ordinal

1

1 reference

26 March 2018

Virginia Bazán

series ordinal

2

1 reference

26 March 2018

language of work or name

English

0 references

publication date

1 September 2011

1 reference

26 March 2018

published in

Vaccine

1 reference

26 March 2018

volume

29 Suppl 3

1 reference

26 March 2018

page(s)

C15-25

1 reference

26 March 2018

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

How many child deaths can we prevent this year?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Global health. Some neglected diseases are more neglected than others

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Comparative impact assessment of child pneumonia interventions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Population-based surveillance of pediatric pneumonia: use of spatial analysis in an urban area of Central Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Pneumococcal disease and vaccination in the Americas: an agenda for accelerated vaccine introduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

A population-based assessment of the disease burden of consolidated pneumonia in hospitalized children under five years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

[The use of chest X-rays for surveillance of bacterial pneumonias in children in Latin America].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

The Vaccine Safety Datalink: a model for monitoring immunization safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Can successful vaccines teach us how to induce efficient protective immune responses?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Timeliness of childhood vaccinations in the United States: days undervaccinated and number of vaccines delayed

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Missed opportunities for immunizations: a review of the evidence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Immunization recall: effectiveness and barriers to success in an urban teaching clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Timeliness of childhood immunizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Knowledge of the childhood immunization schedule and of contraindications to vaccinate by private and public providers in Los Angeles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Production of a unique pneumococcal capsule serotype belonging to serogroup 6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Immunology of bacterial polysaccharide antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Bacterial Polysaccharides as Vaccines — Immunity and Chemical Characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

CD4+ T lymphocytes expressing CD40 ligand help the IgM antibody response to soluble pneumococcal polysaccharides via an intermediate cell type

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Cutting edge: antibody production to pneumococcal polysaccharides requires CD1 molecules and CD8+ T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Glycoprotein conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

CD4+ regulatory T cells: mechanisms of induction and effector function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Antibody regulation of Tcell immunity: implications for vaccine strategies against intracellular pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Nasopharyngeal colonization: a target for pneumococcal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Declining invasive pneumococcal disease mortality in the United States, 1990-2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Effect of pneumococcal conjugate vaccine on pneumococcal meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Decline in pneumonia and acute otitis media after the introduction of childhood pneumococcal vaccination in Liguria, Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Active epidemiologic surveillance of pneumonia and invasive pneumococcal disease in ambulatory and hospitalized infants in Cordoba, Argentina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

[Impact of Streptococcus pneumoniae on pneumonia in Latin American children. SIREVA-Vigía Group]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Invasive pneumococcal diseases in Uruguayan children: comparison between serotype distribution and conjugate vaccine formulations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Etiology and severity of community acquired pneumonia in children from Uruguay: a 4-year study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Outbreak of Streptococcus pneumoniae serotype 1 pneumonia in a United Kingdom school

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

An Outbreak of Streptococcus pneumoniae Serotype 1 in a Closed Community in Southern Israel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Large community outbreak of Streptococcus pneumoniae serotype 5 invasive infection in an impoverished, urban population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Epidemiological differences among pneumococcal serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

inferred from DOI database lookup

7 January 2021

based on heuristic

Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.121

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.07.121

1 reference

26 March 2018

1 reference

26 March 2018